Revogliform 1/0.3 Tablet SR
Marketer
Dr.Revmax Healthcare
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Revogliform 1/0.3 Tablet SR
Combirel SR tablets (1/0.3 mg) are classified as antidiabetic agents, a combination medication for managing type 2 diabetes in adults. This formulation helps regulate blood glucose in diabetic patients. Combirel SR should be ingested with meals, consistently at the same time daily for optimal effectiveness. Dosage is determined and adjusted by your physician based on your blood sugar response. Continued use is crucial, even with well-controlled blood sugar, as abrupt cessation can lead to elevated glucose levels, potentially causing kidney complications, vision impairment, neuropathy, and limb loss. This medication forms one component of a comprehensive diabetes management plan, which necessitates a healthy diet, regular physical activity, and weight management as directed by your healthcare provider. Lifestyle choices significantly influence diabetes control. The most frequent adverse reaction is hypoglycemia (low blood sugar). Familiarize yourself with hypoglycemia symptoms (sweating, dizziness, headache, tremors) and their management. Consistent meals and readily available fast-acting glucose sources (sugary foods, fruit juice) are essential preventative measures. Alcohol consumption, which heightens hypoglycemia risk, should be minimized. Additional potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, cephalalgia, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may occur in some individuals. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before commencing treatment. Pregnant or lactating individuals require medical consultation before use. Regular blood glucose monitoring is necessary, and your doctor may order blood tests to track blood cell counts and liver function.
Uses of Revogliform 1/0.3 Tablet SR
Managing type 2 diabetes
Major Benefits of Revogliform 1/0.3 Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. Administer Revogliform 1/0.3 Tablet SR on an empty stomach.
Common Side effects of Revogliform 1/0.3 Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Revogliform 1/0.3 Tablet SR:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the entire tablet without chewing, crushing, or breaking it. Revogliform 1/0.3 Tablet SR should be administered on an empty stomach.
How Revogliform 1/0.3 Tablet SR works:
Revogliform SR tablets (1 mg/0.3 mg) contain a triple-action formulation to manage diabetes.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use with Revogliform 1/0.3 Tablet SR is contraindicated.
PregnancyCONSULT YOUR DOCTOR
Use of Revogliform 1/0.3 SR tablets during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to the unborn child. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Revogliform 1/0.3 mg tablet is likely not safe for use while breastfeeding. Scant evidence from human studies indicates potential transfer to breast milk with the possibility of infant harm.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The use of Revogliform 1/0.3 Tablet SR is inadvisable for individuals with impaired kidney function and should be avoided, particularly in cases of severe renal disease. Medical advice is essential.
LiverCAUTION
Patients with liver impairment should use Revogliform 1/0.3 Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is advised. In individuals with mild to moderate hepatic dysfunction, Revogliform 1/0.3 Tablet SR therapy typically begins with a reduced dose; however, it's contraindicated in those with severe liver disease.
What if you forget to take Revogliform 1/0.3 Tablet SR :
Should you forget to take a Revogliform 1/0.3 Tablet SR, administer it immediately upon remembrance. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Revogliform 1/0.3 Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently